Article
Primate-Specific LINC03040 Drives Myeloid-Dependent Fibrosis in Human MASH Through a STAT3–S100A8 Regulatory Axis
2026-02-27
Abstract excerpt
<title>Abstract</title> <p> Background While the recent approval of resmetirom marks a historic milestone in MASH therapy, the effective reversal of established cirrhosis (F4) remains a major unmet clinical need. A fundamental limitation in anti-fibrotic drug development is the profound translational gap between murine models and human immunopathology, particularly with respect to species-specific non-coding re...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1cf18b0d-049f-500f-86bc-a09db522251d
- DOI
- 10.21203/rs.3.rs-8780157/v2
